Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

ABTBullishAnalyst Ratingnews

Medium materiality6/10

Abbott Laboratories Upgraded to Buy with Higher Target by Rothschild & Co

Oct 2, 2026, 9:50 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

A price-target hike to 127 and Buy upgrade from a reputable firm implies upside potential and can trigger short-term buying interest, especially since ABT trades in the mid-90s. Historically, such upgrades can lead to a 5–20% move over days to weeks, depending on follow-up coverage and market sentiment.

AI summary

What happened, with direct paths to the underlying reporting

Rothschild & Co boosted Abbott Laboratories' price target from 119 to 127 and upgraded the stock to Buy, signaling renewed confidence in ABT's fundamentals. The move follows no stated earnings change in the article, but the target lift suggests potential near-term upside as analysts recalibrate valuation. With ABT trading around mid- to high-90s, the upgrade could spur a short-term rebound.

Rothschild & Co raises ABT target to 127; upgrades to Buy.
ABT closed at 96.69 on Thursday; upgrade signals upside.
Upgrade implies meaningful near-term upside for ABT from current price.
Target suggests ~31% upside from the recent close.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.